FDA grants accelerated approval for TRUTAKNA™ to treat IgA nephropathy

Filed July 7, 2026 · Period ending July 7, 2026 · ~1 min read

Key Changes

• high

  FDA granted accelerated approval for TRUTAKNA™ (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression, enabling commercial launch and revenue generation.

  Item 8.01 — Other Events verify on EDGAR →